Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 5/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616272 | 0.89 | PDE2A (0.33) | ARPDE2A | |
| SCHEMBL1617282 | 0.84 | ABCC9 (0.38) | PDE3BPDE3ANOTUM | |
| SCHEMBL1616148 | 0.82 | SIRT2 (0.40) | — | |
| SCHEMBL1138761 | 0.78 | AR (0.36) | PDE3BPDE3ANOTUMADCY8ADCY1 | |
| SCHEMBL195564 | 0.77 | HTR2C (0.40) | PDE2A | |
| SCHEMBL1617263 | 0.75 | HTR2C (0.46) | — | |
| SCHEMBL12762087 | 0.75 | HTR2A (0.44) | PDE3BPDE3AADCY8ADCY1POLQ | |
| SCHEMBL22246620 | 0.71 | HTR2A (0.44) | ADCY8ADCY1POLQAR | |
| SCHEMBL3434595 | 0.71 | POLQ (0.47) | PDE3BPDE3ANOTUMADCY8ADCY1 | |
| SCHEMBL18162314 | 0.71 | POLQ (0.47) | PDE3BPDE3ANOTUMADCY8ADCY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | PDE3B 1350/4885PDE3A 614/4885NOTUM 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.